NBY - novabay.com Profit before interest, taxes and amortization

NovaBay Pharmaceuticals generates revenue through the sale of the antimicrobial agent Avenova and related eyelid products. The company's consolidated EBITDA reflects cash flow dynamics, with the value fixed at 0.00. The business is currently focusing on organic growth via online retail while divesting non-core assets. However, pricing pressure in the over-the-counter segment and the risk of losing customer loyalty pose threats to revenue.

Profit before payment of interest, taxes and amortization: novabay.com (NBY) for 11/23/2025 - 04/18/2026

NovaBay - analytical breakdowns and key metrics (NBY)

- market value and analyst target forecast:

Market Price NovaBay|NBY - Analyst Consensus Forecast

- market capitalization statistics:

Market Value NovaBay Pharmaceuticals Inc.|NBY - Total Company Value

- book capitalization data:

Net Assets per Share NovaBay Pharmaceuticals|NBY - Company Book Value|Capitalization to Book Value Ratio novabay.com|NBY - Aggregate Company Assets

- debt level and financial liquidity data:

- company profitability and valuation multiples indicators:

NBY - Net Income|Expected Net Profit NovaBay Pharmaceuticals|NBY - Price to Earnings Ratio|Future Price to Earnings Multiple NovaBay Pharmaceuticals|NBY - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio NovaBay Pharmaceuticals, Inc.|NBY - Operating profit EBITDA|Earnings per share for the trailing year NovaBay Pharmaceuticals|NBY - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth novabay.com|NBY - Earnings per share growth in current year|Expected earnings per share trend next year NovaBay Pharmaceuticals

- sales and revenue data:

NBY - Company Revenue|Company Future Sales Volume NovaBay|NBY - P/S Multiple|Forward P/S Multiple NovaBay Pharmaceuticals, Inc.

Summary company analytics:NBY (novabay.com)

Manufactured product of NovaBay Pharmaceuticals Inc.

This indicator measures net cash flow from operating activities before depreciation and debt service costs, allowing investors to assess the business's fundamental ability to generate cash. An analysis of the overall EBITDA of NovaBay Pharmaceuticals (NBY) reveals the sensitivity of earnings to rising marketing expenses, which NovaBay Pharmaceuticals requires to protect its market position amid intense pressure from generic manufacturers.

Who NovaBay Pharmaceuticals competes with